A New Approach to PCSK9 Therapeutics.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 28264867.
- Also identified by DOI 10.1161/CIRCRESAHA.117.310610 and PMC identifier 5848492.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
PCSK9 inhibition is an effective therapy to reduce LDL cholesterol (LDL-C) and cardiovascular events. A recent study shows that one or two doses of inclisiran, a long-acting synthetic small-interfering RNA (siRNA) that selectively targets hepatic PCSK9, causes a sustained reduction of plasma LDL-C for up to 6 months. Pending further studies of safety and efficacy, this may represent an important addition to the armamentarium for inhibiting PCSK9.
Medical subject headings
- Proprotein Convertase 9
- RNAi Therapeutics